Job Search and Career Advice Platform

Ativa os alertas de emprego por e-mail!

Specialist - External Quality Assurance

Nexcella, Inc.

Teletrabalho

BRL 80.000 - 120.000

Tempo integral

Hoje
Torna-te num dos primeiros candidatos

Cria um currículo personalizado em poucos minutos

Consegue uma entrevista e ganha mais. Sabe mais

Resumo da oferta

A biopharmaceutical company is seeking a Specialist in External Quality Assurance to oversee compliance with quality standards in manufacturing and testing. The ideal candidate will review and approve quality investigations, monitor production, and support audit readiness activities. A Bachelor's degree in a relevant field and 3-5 years of QA experience in the biopharmaceutical industry are required. Strong knowledge of cGMP is essential for success in this role.

Qualificações

  • 3 – 5 years of QA experience in the biopharmaceutical or cell/gene therapy industry.
  • Strong knowledge of cGMP, ICH Q7 / Q10, FDA 21 CFR Parts 210 / 211.
  • Experience with CDMO oversight and deviation management.

Responsabilidades

  • Review and approve deviations, OOS investigations, and CAPAs from CDMOs.
  • Monitor manufacturing campaigns and production activities.
  • Collaborate with cross‑functional teams to ensure compliance.

Conhecimentos

QA experience in biopharmaceutical industry
Knowledge of cGMP
Communication skills
Problem-solving skills

Formação académica

Bachelor's degree in Life Sciences, Chemistry, Biochemistry, Engineering
Descrição da oferta de emprego
Specialist – External Quality Assurance

São Paulo, Brazil / Remote

Nexcella, Inc.

Our 3 Core Values
  • Intelligence
  • Integrity
  • Initiative

Our mission is to harness the immune system through innovative cell therapies and other modalities to deliver widely accessible cures. Patients are waiting!

What You'll Do :

The Specialist, External Quality Assurance (EQA) will provide oversight of Contract Development and Manufacturing Organizations (CDMOs) and testing laboratories to ensure compliance with cGMP, regulatory requirements, and company quality standards. This role is critical in supporting ongoing manufacturing campaigns, batch release, and ensuring timely resolution of quality events.

What We Look For : Key Responsibilities
  • Review and approve deviations, Out-of-Specification (OOS) investigations, CAPAs, and change controls from CDMOs and external testing laboratories.
  • Monitor manufacturing campaigns, production activities, and resolve issues during routine manufacturing.
  • Review and approve QC / analytical results and Certificates of Analysis from CDMOs / external labs.
  • Review and approve production lot records for compliance prior to disposition.
  • Perform GMP reviews of incoming documentation (batch records, test data, release packages).
  • Ensure timely escalation and resolution of manufacturing and quality issues.
  • Collaborate with internal cross‑functional teams (QA, QC, Supply Chain, Regulatory, CMC) to ensure readiness for release and regulatory filings.
  • Support audit readiness activities for Regulatory Authority inspections.
Qualifications
  • Bachelor's degree in Life Sciences, Chemistry, Biochemistry, Engineering, or related discipline.
  • 3 – 5 years of QA experience in the biopharmaceutical or cell / gene therapy industry.
  • Strong knowledge of cGMP, ICH Q7 / Q10, FDA 21 CFR Parts 210 / 211.
  • Experience with CDMO oversight, lot release, and deviation management.
  • Excellent communication and problem‑solving skills.
About Nexcella, Inc.

Nexcella, Inc. is a subsidiary of Immix Biopharma, Inc. (ImmixBio) (Nasdaq : IMMX), a clinical‑stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases. Our lead candidate is sterically‑optimized BCMA‑targeted chimeric antigen receptor T (CAR‑T) cell therapy NXC‑201 with a “digital filter” that filters out non‑specific activation. NXC‑201 is being evaluated in the U.S. multi‑center study for relapsed / refractory AL Amyloidosis NEXICART‑2 (NCT06097832), with a registrational design. Interim results were presented at ASCO 2025. NXC‑201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at and

Obtém a tua avaliação gratuita e confidencial do currículo.
ou arrasta um ficheiro em formato PDF, DOC, DOCX, ODT ou PAGES até 5 MB.